Innovation Pharmaceuticals Inc (IPIX)

[kfcyahoo]

froll,

You must of nmissed my post of Tuesday night(post #225965).

I broke down duration in days from last patient visit since trial. I compared duration to actual(final) patient enrollment to determine the average rate of patient enrollment per trial duration, which is last figure of each row with units shown as p/d(patients per day).

Hope that helps.

My Tuesday post ranking for duration was:

#1 Valeant .70p/d
#2 Kayowa .51p/d (they have rights to Brodalumab which was developed by Amgen, Inc. as AMG 827. AstraZeneca and Amgen took through ph3 trials but after of reports of patients having "events of suicidal ideation and behavior", Amgen threw that baby out. AstraZeneca gave rights in certain Asian territories such as Japan, where Kyowa Hakko Kirin has rights to brodalumab and continued as KHK4827, AstraZeneca then formed a partnership with Valeant in which Valeant took over exclusive rights to develop and commercialize brodalumab. Valeant has since sold off rights to Leo Pharma(no joke) to commercialize brodalumab in Europe. It been approved (since Feb 2017) in the U.S to treat moderate to severe plaque psoriasis in people who have not improved with other treatments.

There are many reasons why so many psoriasis patients(many of whom have partaken in clinical trials) were in involved with fda's 3/17/16 Patient Focused Drug Development for Psoriasis conference.

#3. IPIX (Innovation Pharmaceuticals) .51p/d

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=140321231